Watson Labs receives AP status for Ciprofloxacin Hydrochloride ANDA076794
Watson Labs has received an Abbreviated Approval (AP) for its ANDA076794 application for Ciprofloxacin Hydrochloride.
Asset / Drug
Drug and asset intelligence for Watson with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.